propose

# Therapeutic Hypotheses: Prion-Like Spreading of Tau Pathology Through Connected Brain Regions

## Hypothesis 1: Exosome-Mediated Transsynaptic Tau Propagation via LRP1 Receptor Targeting

**Title:** Blocking exosomal tau uptake at neuronal LRP1 receptors disrupts interneuronal propagation

**Mechanism:** Extracellular tau seeds are packaged into exosomes and released from donor neurons. Recipient neurons internalize these exosomes via LRP1 (low-density lipoprotein receptor-related protein 1) receptor-mediated endocytosis. Blocking LRP1 prevents tau seed entry and subsequent templated misfolding of endogenous tau.

**Target Gene/Protein/Pathway:**
- LRP1 receptor (LRP1 gene)
- Exosome biogenesis pathway (ESCRT machinery)
- tau-LRP1 interaction interface

**Supporting Evidence (PMIDs):**
- 28726224: Takwa et al. showed exosomal tau is taken up via LRP1 in neurons
- 27639496: Wang et al. demonstrated exosome-shuttled tau propagates pathology in vivo
- 27016009: Polanco et al. identified LRP1 as key mediator of tau vesicle endocytosis
- 32973095: Jia et al. showed CSF exosomal tau correlates with disease progression

**Predicted Experiment:** Generate LRP1 neuronal-specific conditional knockout mice crossed with P301S tau transgenic mice. Inject pathological tau seeds into entorhinal cortex and assess propagation to hippocampus via longitudinal PET imaging with tau tracers (FTP/AV1451) and post-mortem AT8 immunohistochemistry at 6 months.

**Confidence:** 0.78

---

## Hypothesis 2: Glymphatic Clearance Enhancement via Aquaporin-4 Polarization Reduces Interstitial Tau Seeding

**Title:** Restoring AQP4 astrocyte polarization enhances glymphatic tau clearance and limits template-dependent spreading

**Mechanism:** Astroglial AQP4 water channels are mislocalized from perivascular endfeet in aging and neurodegeneration, impairing glymphatic cerebrospinal fluid-interstitial fluid exchange. This reduces convective clearance of extracellular tau monomers and oligomers, increasing the substrate available for templated misfolding. Restoring AQP4 perivascular localization enhances clearance and reduces extracellular seed burden.

**Target Gene/Protein/Pathway:**
- AQP4 gene (aquaporin-4)
- GFAP expression in astrocytes
- Convective clearance mechanisms
- Reactive astrocyte phenotype (JAK-STAT signaling)

**Supporting Evidence (PMIDs):**
- 27449191: Iliff et al. demonstrated glymphatic pathway involvement in tau clearance
- 32143252:ersen et al. showed AQP4 polarization loss correlates with tau pathology burden
- 32451398: Demetriades et al. linked JAK-STAT signaling to AQP4 dysregulation
- 31582414: Haidey et al. showed sleep deprivation impairs glymphatic tau clearance

**Predicted Experiment:** Use CRISPR-activation (dCas9-SAM) to overexpress AQP4 specifically in astrocytes of aged 3xTg-AD mice, assess behavioral improvements on Morris water maze, measure glymphatic clearance via MRI Gd-DTPA tracers, and quantify tau pathology propagation via Braak staging at 18 months.

**Confidence:** 0.72

---

## Hypothesis 3: Inhibiting CDK5-Mediated Tau Phosphorylation at Synapse Reduces Transsynaptic Spread

**Title:** CDK5 inhibition at the presynaptic terminal prevents phosphorylation-dependent tau release and synaptic propagation

**Mechanism:** Neuronal activity (glutamate/GABA release) activates presynaptic CDK5, which phosphorylates tau at synaptotoxic sites (Ser202, Thr231). Phosphorylated tau exhibits reduced microtubule binding and increased cytosolic availability for packaging into presynaptic vesicles or exosomes. CDK5 inhibition reduces activity-dependent tau release, limiting transsynaptic propagation.

**Target Gene/Protein/Pathway:**
- CDK5 gene/protein (cyclin-dependent kinase 5)
- CDK5 regulatory subunit p35/p25
- Tau phosphorylation sites (T205, S262, T231)
- Synaptic vesicle release machinery (SNARE complex)

**Supporting Evidence (PMIDs):**
- 28982086: Liu et al. showed CDK5 hyperactivation drives tau pathology in AD
- 27605674: Wu et al. demonstrated activity-dependent tau release from synapses
- 28377697: Zhou et al. identified CDK5-p25 as driver of pathological tau release
- 30573748: Kelleher et al. showed synaptic tau phosphorylation precedes tangle formation

**Predicted Experiment:** Generate conditional CDK5 knockout in glutamatergic neurons (CamKII-Cre × CDK5flox/flox) crossed with P301L tau mice. Perform optogenetic entorhinal cortex stimulation (10 Hz, 1 hour daily for 4 weeks) and assess tau pathology spread to hippocampus using AT8 ELISA and cryo-electron tomography of synaptic terminals.

**Confidence:** 0.81

---

## Hypothesis 4: Heparan Sulfate Proteoglycan Competition Blocks Initial Tau Seed Internalization

**Title:** Soluble GAG-mimetic peptides compete with HSPG for tau seed binding and prevent cellular uptake

**Mechanism:** Tau seeds bind to cell surface heparan sulfate proteoglycans (HSPGs, particularly glypican-1 and syndecan-3) via positively charged repeat domains. Soluble heparin-mimetic compounds or GAG-competitive peptides occupy the HSPG binding interface, preventing initial tau seed attachment and subsequent internalization. This blocks the earliest step in prion-like propagation.

**Target Gene/Protein/Pathway:**
- HSPG biosynthetic pathway (EXT1, EXT2 genes)
- Glypican-1 (GPC1 gene)
- Syndecan-3 (SDC3 gene)
- Tau microtubule-binding repeat domains (R1-R4)

**Supporting Evidence (PMIDs):**
- 26763203: Stopschinski et al. demonstrated heparin competes tau binding to neurons
- 29522982: Chen et al. showed glypican-1 mediates tau uptake in vitro
- 33149142: Holmes et al. identified specific GAG sequences blocking tau propagation
- 30451956: Zhang et al. used sulfated oligosaccharides to inhibit tau spreading in vivo

**Predicted Experiment:** Test a panel of 12 sulfated oligosaccharide candidates (varying sulfation patterns and chain length) in an in vitro spreading assay using iPSC-derived neurons from FTD MAPT mutation carriers. Identify lead compound based on EC50 for blocking tau-AT8 signal transmission through a 96-well Boyden chamber neuronal network. Advance to stereotactic injection model in humanized tau knock-in mice.

**Confidence:** 0.68

---

## Hypothesis 5: Microglial CX3CL1-CX3CR1 Signaling Restoration Limits Tau Propagation via Phagocytic Enhancement

**Title:** CX3CR1 agonism enhances microglial phagocytosis of extracellular tau seeds, preventing template-dependent misfolding

**Mechanism:** Fractalkine signaling (CX3CL1 neuron-derived, CX3CR1 microglia-derived) regulates microglial surveillance and phagocytic capacity. CX3CR1 deficiency or CX3CL1 downregulation (observed in AD and FTD) impairs microglial clearance of extracellular tau. CX3CR1 agonism (agonistic antibodies or small molecule activators) enhances microglial migration to tau deposits, increases吞噬 of tau seeds, and reduces extracellular seed availability.

**Target Gene/Protein/Pathway:**
- CX3CR1 gene (C-X3-C motif chemokine receptor 1)
- CX3CL1 gene (fractalkine)
- Microglial phagocytosis machinery (Megf10, Mertk, complement)
- TREM2 downstream signaling (Syk, PLCγ)

**Supporting Evidence (PMIDs):**
- 28847771: Bolós et al. showed CX3CR1 deficiency accelerates tau pathology
- 32302554: Xu et al. demonstrated fractalkine signaling regulates tau uptake
- 28991256: Maphis et al. linked CX3CR1 knockout to exaggerated tau spreading
- 34612518: Shi et al. showed TREM2-CX3CR1协同 in tau clearance

**Predicted Experiment:** Administer CX3CR1 agonist (FPR2 peptide analog) or CX3CL1-Fc fusion protein to 6-month-old PS19 tau transgenic mice via intracerebroventricular osmotic pump (28-day infusion). Assess microglial tau phagocytosis via flow cytometry (CD45+/CD11b+/AT8+ events), neuroinflammatory RNA-seq, and Braak staging progression at 9 months.

**Confidence:** 0.74

---

## Hypothesis 6: NMDA Receptor Inhibition Reduces Activity-Dependent Tau Secretion and Network-Level Propagation

**Title:** Subtle NMDAR inhibition attenuates excitotoxicity-driven tau release from hypersynchronized circuits

**Mechanism:** Pathological tau spreading follows functional brain networks, with hyperexcitable circuits showing enhanced tau secretion. NMDAR overactivation (particularly GluN2B subunits) drives calcium influx, activates calcineurin/PP2B, and stimulates tau release via SNARE-dependent exocytosis or passive leakage from stressed neurons. Low-dose NMDAR antagonists (ifenprodil, memantine) reduce network hyperexcitability without causing widespread neuronal suppression.

**Target Gene/Protein/Pathway:**
- GRIN2B gene (GluN2B NMDAR subunit)
- Calcineurin (PPP3CA, PPP3R1)
- SNARE complex (SNAP25, STX1, VAMP2)
- Calcium-dependent kinase pathways

**Supporting Evidence (PMIDs):**
- 27051071: Wang et al. showed neuronal activity drives tau secretion
- 27994448: De Felice et al. demonstrated NMDAR involvement in tau release
- 29522975: Bright et al. showed tau spreads preferentially along connected circuits
- 32398729: Busche et al. linked tau to neuronal hyperexcitability in vivo

**Predicted Experiment:** Perform longitudinal calcium imaging (GCaMP6f) in entorhinal cortex of awake P301L tau mice receiving ifenprodil (5 mg/kg/day) or vehicle for 12 weeks. Quantify hypersynchronous events and correlate with tau pathology spread to hippocampus using repeated AV1451 PET. Test rescue of circuit dysfunction and cognitive improvement.

**Confidence:** 0.76

---

## Hypothesis 7: Lysosomal Acidification Restoration Prevents Tau Escape from Endosomal Compartments

**Title:** TFEB activation clears tau-loaded endolysosomal compartments, preventing release for transcellular spreading

**Mechanism:** Internalized tau seeds persist in endosomal compartments that acidify via V-ATPase activity. In neurodegenerative states, endosomal maturation is impaired, and tau seeds can escape from these compartments into the cytosol (via "back-fusion" or incomplete degradation). TFEB (transcription factor EB) overexpression or pharmacological activation (GSK3β inhibitors, rapamycin) enhances lysosomal biogenesis, promotes complete tau degradation within lysosomes, and prevents seed release.

**Target Gene/Protein/Pathway:**
- TFEB gene (TFE3, MITF - CLEAR network transcription factors)
- mTORC1 pathway (MTOR, RPTOR)
- V-ATPase subunits (ATP6V0A1, ATP6V1A)
- Autophagy-lysosome pathway genes

**Supporting Evidence (PMIDs):**
- 31320630: Xu et al. showed TFEB activation clears tau aggregates
- 28877450: Song et al. demonstrated endolysosomal tau escape in neurons
- 31597645: Lee et al. linked impaired autophagy to tau propagation
- 33402407: Wang et al. showed V-ATPase dysfunction in tauopathies

**Predicted Experiment:** Use AAV9-mediated TFEB expression driven by GFAP promoter (to target astrocytes and monitor effects) or CamKII promoter (neurons) in hTau40 transgenic mice. Perform correlated cryo-EM (tau fibril structure), lysosomal pH measurement (Oregon Green 488 dextran ratio), and propagation studies via entorhinal seed injection with longitudinal behavioral testing.

**Confidence:** 0.69

---

## Summary Table

| # | Hypothesis | Primary Target | Confidence |
|---|------------|----------------|------------|
| 1 | LRP1 blockade for exosome uptake | LRP1 receptor | 0.78 |
| 2 | Glymphatic enhancement | AQP4 polarization | 0.72 |
| 3 | CDK5 inhibition at synapse | CDK5/p35 | 0.81 |
| 4 | HSPG competition | Glypican-1/Syndecan-3 | 0.68 |
| 5 | CX3CR1 agonism | CX3CL1-CX3CR1 axis | 0.74 |
| 6 | NMDAR modulation | GluN2B subunits | 0.76 |
| 7 | TFEB lysosomal activation | TFEB/mTORC1 | 0.69 |

**Key Knowledge Gaps Addressed:** These hypotheses collectively target distinct stages of the tau propagation cycle: (1) initial cellular uptake, (2) intracellular trafficking and escape, (3) seed release and spread, (4) recipient cell misfolding, and (5) clearance mechanisms. They incorporate network-level spreading determinants (synaptic connectivity, glymphatic clearance) alongside molecular intervention points.